In an unusual rebuke, AbbVie (ABBV) was reprimanded by the Food and Drug Administration for sloppy procedures when reviewing complaints of deaths that were reported in connection with three of its medicines, including the best-selling Humira rheumatoid arthritis treatment.

Following an inspection at a North Chicago, Il., facility late last year, FDA examiners found the company failed to “thoroughly investigate” complaints over certain syringe kits for its Lupron medication that were associated with deaths, according to an inspection report that was issued by the agency last Dec. 15, and was obtained by STAT, but is not yet available on the FDA web site. Lupron is used to treat endometriosis and uterine fibroids, among other illnesses.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • They outsource the case processing to India. Merck outsources all adverse event reporting to India, China, and Brazil. Abbvie outsources to India. All of a patient’s information and data regarding the AEs go to these foreign countries. Has the FDA really audited this process since they want qualified people involved in handling adverse events? Has HIPAA? Has the Department of Labor?

  • There are thousands of us that have been severely hurt by Lupron.
    FDA, AbbVie, and Doctors are well aware of this and yet NO ONE WILL TAKE ON BIG MONEY, maybe it’s because they all have stock with the drug company or maybe many of them are getting paid to cover up this deadly drug!
    I almost forgot that we have also sent a petition to CONGRESS as well!
    I hope one day everyone involved with Lupron will have to pay for what they have done and continue to do to everyone with this poison.

    • Looks like we have another correctionist back on campus. Posters watch your spelling when Mike Z is around! Hey pal, I worked for Abbott before there was Abbvie and probably before you reached puberty, but whatever you call them they both have a long history of ignoring AE’s. Now you can go back to your thesaurus and return when you have something to contribute besides grammatical, spelling or historical errors.

  • Simple fix. When these terrible results are found the CEO should be put on the protocol until they expierence the results reported. The industry will become the safest in history,after that.

    • I can’t take any comment seriously when easy to spell words are not spelled correctly. It makes me question your level of education.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy